Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

642
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Cancer Vaccines01:30

Cancer Vaccines

492
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
492
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial and ethnic disparities in receipt of guideline-concordant treatment for early-stage non-small cell lung cancer.

Cancer causes & control : CCC·2026
Same author

Prophylaxis with diltiazem decreases arrhythmia rate when compared to beta-blocker following lobectomy.

Journal of thoracic disease·2026
Same author

Supercharged Pedicled Jejunal Interposition for Esophageal Reconstruction: A Systematic Review and Meta-analysis of Adult and Pediatric Patients.

Journal of reconstructive microsurgery·2026
Same author

Mentorship, Sponsorship, and Beyond-Additional Considerations for Women in Cardiothoracic Surgery.

The Annals of thoracic surgery·2026
Same author

Patient's Participation in Lung Cancer Surgical Treatment: The Role of Patient-Reported Outcomes and Advocacy.

Surgical oncology clinics of North America·2025
Same author

Evaluation of a Perioperative Hypothermia Prevention Protocol in Thoracic Surgery with Comparison to Historical Control.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2025
Same journal

A CALL FOR STANDARDIZATION OF HYBRID ARCH FROZEN ELEPHANT TRUNK OUTCOMES REPORTING.

The Journal of thoracic and cardiovascular surgery·2026
Same journal

Pediatric Mitral Valve Surgery: Current Practice from the European Congenital Heart Surgeons Association Congenital Database Analysis.

The Journal of thoracic and cardiovascular surgery·2026
Same journal

Rethinking Failure to Rescue in Cardiac Surgery.

The Journal of thoracic and cardiovascular surgery·2026
Same journal

Undersized Fontan conduits are not without risk.

The Journal of thoracic and cardiovascular surgery·2026
Same journal

Predicting high-risk recipients or high-risk donation after circulatory death hearts?

The Journal of thoracic and cardiovascular surgery·2026
Same journal

Outcomes of donation after circulatory death heart transplantation in recipients with pulmonary hypertension.

The Journal of thoracic and cardiovascular surgery·2026
See all related articles

Related Experiment Video

Updated: Aug 27, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Commentary: Another win for immunotherapy

Alison Halpern Mungo1, Elizabeth A David1

  • 1Section of General Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado, Aurora, Colo.

The Journal of Thoracic and Cardiovascular Surgery
|October 2, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

627
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Related Experiment Videos

Last Updated: Aug 27, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

627
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K